AU5620598A - Pharmaceutical preparations of glutathione and methods of administration thereof - Google Patents

Pharmaceutical preparations of glutathione and methods of administration thereof

Info

Publication number
AU5620598A
AU5620598A AU56205/98A AU5620598A AU5620598A AU 5620598 A AU5620598 A AU 5620598A AU 56205/98 A AU56205/98 A AU 56205/98A AU 5620598 A AU5620598 A AU 5620598A AU 5620598 A AU5620598 A AU 5620598A
Authority
AU
Australia
Prior art keywords
glutathione
administration
methods
pharmaceutical preparations
bolus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56205/98A
Other languages
English (en)
Inventor
Harry B Demopoulos
Myron L. Seligman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antioxidant Pharmaceuticals Corp
Original Assignee
Antioxidant Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21874315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5620598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antioxidant Pharmaceuticals Corp filed Critical Antioxidant Pharmaceuticals Corp
Publication of AU5620598A publication Critical patent/AU5620598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
AU56205/98A 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof Abandoned AU5620598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3410196P 1996-12-31 1996-12-31
US60034101 1996-12-31
PCT/US1997/023879 WO1998029101A1 (en) 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof

Publications (1)

Publication Number Publication Date
AU5620598A true AU5620598A (en) 1998-07-31

Family

ID=21874315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56205/98A Abandoned AU5620598A (en) 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof

Country Status (8)

Country Link
US (5) US6159500A (enExample)
EP (1) EP0957901B1 (enExample)
JP (1) JP2001507696A (enExample)
AT (1) ATE448782T1 (enExample)
AU (1) AU5620598A (enExample)
CA (2) CA2650204A1 (enExample)
DE (1) DE69739663D1 (enExample)
WO (1) WO1998029101A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744593A (en) * 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
DE69826521T2 (de) * 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
CA2419845A1 (en) 1999-08-17 2002-02-22 Phyllis G. Paterson Improved treatment for acute physical insult to the central nervous system
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
ES2235415T3 (es) * 1999-09-21 2005-07-01 Enzo Leone Composiciones antivirales que comprenden yohimbina como principio activo.
WO2001068069A2 (en) * 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
AU780161B2 (en) * 2000-04-07 2005-03-03 Sang Geon Kim Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
GB0008689D0 (en) * 2000-04-07 2000-05-31 Nokia Networks Oy A method and system for processing signals
AU6124401A (en) * 2000-05-09 2001-11-20 Nitromed Inc Infrared thermography and methods of use
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
CA2459556A1 (en) * 2001-09-14 2003-03-27 Roke Manor Research Limited Low cost tagging system
US6726809B2 (en) * 2001-09-26 2004-04-27 Albany International Corp. Industrial process fabric
CA2461557A1 (en) * 2001-10-16 2003-04-24 University Of Kansas Novel prodrugs of n-h bond-containing compounds and methods of making thereof
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
US7407986B2 (en) * 2001-12-18 2008-08-05 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
US20040213829A1 (en) * 2002-04-15 2004-10-28 Coleman Henry D. Dietary supplement
US20030194453A1 (en) * 2002-04-15 2003-10-16 Coleman Henry D. Dietary supplement
US20060099239A1 (en) * 2002-04-15 2006-05-11 Coleman Henry D Dietary supplement for promoting removal of heavy metals from the body
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
WO2003092479A2 (en) * 2002-05-03 2003-11-13 Luc Montagnier Treatments and methods for the treatment, diagnosis and prophylaxis
US20100316700A1 (en) * 2002-11-07 2010-12-16 Guilford F Timothy Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
AU2003297028A1 (en) * 2002-12-13 2004-07-09 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US8283435B2 (en) 2003-02-21 2012-10-09 Metabolix, Inc. PHA adhesive compositions
WO2004076583A1 (en) * 2003-02-21 2004-09-10 Metabolix Inc. Pha adhesive compositions
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
AU2004283461B2 (en) * 2003-10-15 2010-02-11 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
EP1964879B1 (en) * 2003-12-30 2012-06-13 Metabolix, Inc. Nucleating agents
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
EP1768499A4 (en) * 2004-05-24 2012-01-04 David M Ott MEDICAL PRODUCTS CONTAINING RELATED ORGANOSOUFRES GROUPS
CA2578748C (en) * 2004-09-03 2014-10-14 Kyowa Hakko Kogyo Co., Ltd. Composition and method for prevention or treatment of stomatitis
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
ES2395555T3 (es) * 2004-11-07 2013-02-13 Your Energy Systems, LLC Formulación liposomal para la administración oral de glutatión (reducido)
CN101084003A (zh) * 2004-12-21 2007-12-05 重症救护联络公司 治疗性营养组合物或联合药物及其使用方法
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
US8232240B2 (en) * 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
CA2615319A1 (en) * 2005-07-13 2007-01-18 Al Czap Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
US20110112032A1 (en) * 2005-09-12 2011-05-12 Ming-He Huang Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases
GB2430364A (en) * 2005-09-22 2007-03-28 Carl Ernest Alexander Soft agar bolus for oral drug delivery
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
KR101538727B1 (ko) 2006-10-05 2015-07-22 이카리아 인코포레이티드 액체 칼코게나이드 조성물 및 이의 제조방법과 사용방법
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
US20080318864A1 (en) * 2007-06-25 2008-12-25 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
GB0722923D0 (en) * 2007-11-22 2008-01-02 Uhi Millennium Inst Improved anti-platelet compositions
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法
EP2255823A4 (en) * 2008-02-15 2011-03-09 Ajinomoto Kk GUT IMMUNE-STIMULATOR
US20100098733A1 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
JP5208028B2 (ja) * 2009-03-16 2013-06-12 学校法人帝京大学 Ｅｄ評価方法
US8313456B2 (en) * 2009-06-30 2012-11-20 Palo Alto Research Center Incorporated Drug-transfer device, drug-delivery system incorporating the same, methods of fabricating the same, and methods of enabling administration of a drug
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011047013A1 (en) * 2009-10-13 2011-04-21 Novan, Inc. Nitric oxide-releasing coatings
WO2011091807A1 (en) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant and glutathione for treatment of cancer
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
EP2815760B1 (en) * 2012-02-15 2019-10-09 Kyowa Hakko Bio Co., Ltd. Agent for preventing or ameliorating vascular endothelial malfunction
US20130323324A1 (en) * 2012-06-01 2013-12-05 Franco Cavaleri Vanadium and vanadyl amino acid complexes
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof
CN104755538B (zh) 2012-08-17 2018-08-31 Cj 第一制糖株式会社 用于聚合物共混物的生物基橡胶改性剂
ES2659199T3 (es) * 2012-09-28 2018-03-14 Kyowa Hakko Bio Co., Ltd. Agente para aumentar la inmunidad que contiene glutatión
US20140100283A1 (en) * 2012-10-05 2014-04-10 Atlantic Pro Nutrients, Inc. dba XYMOGEN Method to Increase Absorption and Bioavailability of Oral Glutathione
EP2990048B1 (en) * 2013-01-21 2023-03-01 Kyowa Hakko Bio Co., Ltd. Nitric oxide concentration elevating agent
US10669417B2 (en) 2013-05-30 2020-06-02 Cj Cheiljedang Corporation Recyclate blends
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
AU2015317877A1 (en) * 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
CA3081693C (en) * 2014-10-09 2022-01-11 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the reduction of heavy metal toxicity
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
WO2017091737A1 (en) * 2015-11-25 2017-06-01 Molecular Defenses Corporation Pharmaceutical formulations
US10702590B2 (en) * 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US20180008665A1 (en) * 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
CN111615395B (zh) 2017-11-17 2024-08-06 莱诺翁股份有限公司 稳定的抗坏血酸组合物及其使用方法
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US12653854B2 (en) 2019-04-15 2026-06-16 Quicksilver Scientific, Inc. Intra-oral nanoemulsion including monolayer surfactant bound particles for balancing histamine response
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
EP3733197A1 (en) * 2019-04-30 2020-11-04 Stephen N. Pitcher Anaerobic antioxidant composition
JP7853071B2 (ja) * 2020-11-04 2026-04-28 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
CN113164608A (zh) * 2021-02-02 2021-07-23 学校法人日本医科大学 抗病毒剂
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액
IT202200007238A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
WO2023199241A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof
CR20240486A (es) * 2022-04-12 2025-01-20 Uriach Italy S R L Composición compuesta por n-acetilcisteína, itamina d y preferentemente glutatión, sus usos, y sus composiciones farmaceuticas y nutracéuticas
IT202200007232A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007229A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
KR102602347B1 (ko) * 2022-05-09 2023-11-15 천현수 위장내 발암성 엔-니트로사민 생성 억제 및 장내 산화질소 생성 촉진용 천연 조성물 및 이의 용도
CN117169201B (zh) * 2023-08-21 2026-07-14 杭州师范大学 一种基于碱性磷酸酶诱导的双路径复合显色传感器及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
FR2461002A1 (fr) 1979-07-13 1981-01-30 Inst Nat Sante Rech Med Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede
US4381307A (en) 1980-10-31 1983-04-26 Merck & Co., Inc. Soft tertiary amine esters of bio-affecting carboxylic acids
US4477435A (en) 1981-05-19 1984-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for regenerating corneal epithelium
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4454125A (en) 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4770877A (en) 1982-08-03 1988-09-13 Boston Biomedical Research Institute Isolation of a high molecular weight aortic endothelial cell growth inhibitor
US4534967A (en) 1982-08-03 1985-08-13 Boston Biomedical Research Institute Cell proliferation inhibitor and method of preparation
FI864293A7 (fi) 1985-02-26 1986-10-23 Univ Johns Hopkins Uusverisuonituksen inhibiittoreita ja niiden valmistus- ja käyttömene telmiä.
JPS62169723A (ja) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5061729A (en) 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
IT1231012B (it) 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
JP2919870B2 (ja) * 1989-09-29 1999-07-19 千寿製薬株式会社 肝障害抑制剤
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
DE69233529T2 (de) 1991-02-01 2005-11-24 Daiichi Suntory Pharma Co., Ltd. Orale antibakterielle Zusammensetzungen und Verfahren zur Verbesserung der Resorption von Penem-oder Carbapenem-Antibiotika im Magen-Darm-Trakt
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
EP0746202A4 (en) 1992-01-06 1997-06-25 Health Maintenance Programs COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
US5204114A (en) 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US6319687B1 (en) 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5840686A (en) 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
AU4701593A (en) * 1993-07-22 1995-02-20 Esseti S.A.S. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C. Oral pharmaceutical compositions comprising reduced glutathion
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5985926A (en) 1993-11-01 1999-11-16 Cell Therapeutics, Inc. Method for inhibiting intracellular viral replication
US5679541A (en) 1994-02-14 1997-10-21 California Institute Of Technology Programmed cell death antagonist protein
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6015665A (en) 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5929063A (en) 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5674907A (en) 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
US5681711A (en) 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
WO1996036704A1 (en) * 1995-05-19 1996-11-21 New York Blood Center, Inc. Methods of use of phthalocyanines to inactivate blood borne parasites
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases

Also Published As

Publication number Publication date
US6423687B1 (en) 2002-07-23
US6350467B1 (en) 2002-02-26
EP0957901A1 (en) 1999-11-24
CA2650204A1 (en) 1998-07-09
US6586404B1 (en) 2003-07-01
WO1998029101A1 (en) 1998-07-09
DE69739663D1 (de) 2009-12-31
CA2276183C (en) 2009-06-09
EP0957901A4 (en) 2006-04-12
US6159500A (en) 2000-12-12
CA2276183A1 (en) 1998-07-09
EP0957901B1 (en) 2009-11-18
ATE448782T1 (de) 2009-12-15
JP2001507696A (ja) 2001-06-12
US6204248B1 (en) 2001-03-20

Similar Documents

Publication Publication Date Title
EP0957901A4 (en) PHARMACEUTICAL GLUTATHION PREPARATIONS AND METHODS OF ADMINISTRATION
CA2152062A1 (en) Enhanced Solubility Pharmaceutical Solutions
CA2219991A1 (en) Taste masking pharmaceutical composition for oral administration
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
MY118371A (en) Tetrahydrolipstatin containing compositions
MY125662A (en) Pharmaceutical formulations containing darifenacin
IE871584L (en) Sustained release capsule.
IE870993L (en) Nasal administration compositions.
EP0225189A3 (en) Targeted enteral delivery system
WO1998006380A3 (en) Dosage form for providing ascending dose of drug
AU5945296A (en) Medicament for nasal administration
IE821214L (en) Medicament
AU7294196A (en) Stable pharmaceutical forms of administration containing parathormone
AU2084801A (en) Antiviral medication
AU5811996A (en) Nanoparticles for oral administration of pharmaceutical agen ts of low solubility
IL78336A (en) Compositions for delivery of orally administered fat-soluble drugs
AU2229392A (en) Method for the preparation of prolonged-release oral pharmaceutical forms containing active substances having a solubility dependent upon the ph value
MX9803478A (es) Una composicion farmaceutica para el tratamiento de enfermedades autoinmunes.
AU563822B2 (en) Pharmaceutical composition of piroxicam and 5'-guanylic acid or n-acetyl-l-methionine
EP0271151A3 (en) Azumolene dosage form
PL325242A1 (en) Method of obtaining solid drug administration forms for very low dosage drugs
AU2405292A (en) Method of producing well tolerated drugs containing human proteins for administration by infusion or injection
AU4565597A (en) Colonic delivery of weak acid drugs
AU1066897A (en) Pharmaceutical preparations for oral administration and process for their production
GB9420748D0 (en) 1,5 benzodiazepine derivatives